CMML/JMML PDXs: As easy as 1, 2, NSG-SGM3

Abstract

In this issue of Blood, Yoshimi et al describe a simple method to establish patient-derived xenografts (PDXs) of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) with remarkable efficiency. These morphologically, immunophenotypically, and genetically accurate models will pave the way for in vivo biological studies and preclinical testing of novel therapies.1